Dinner Short Course*
Thursday, May 22, 2014 | 6:00 - 9:00 PMWestin Boston Waterfront | Boston, MA
Dinner Short Course: Current Trends in Crystallization and Polymorphism: Experiment and Prediction - CANCELLED
Reproducible production of crystal forms is a serious issue endemic in pharmaceutical development. The current state of the art in prediction of crystalline form and polymorphs will be discussed. Latest experimental approaches of crystallization will be reviewed.
6:00 pm Chairperson’s Opening Remarks: Property-Based Drug Design: Crystal Engineering and Polymorphism
Terry Richard Stouch, Ph.D., President, Science for Solutions, LLC - Biography
The solid state form of a compound can be the barrier between a well-crafted drug and the market. Proper crystal engineering can not only progress a compound to the market, it can compensate for poor innate solubility. Despite the quality of a compound and the initial crystal form, unforeseen polymorphism can cause setbacks and result in a product being pulled from the pharmacy shelves. In this short course, highly experienced experts in the fields of crystal engineering and prediction will discuss the state of the art and provide case studies.
6:10 Crystal Engineering Approaches to Improve the Biopharmaceutical Properties of Materials
Denette Murphy, Ph.D., Principal Scientist, Drug Product Science and Technology, Bristol-Myers Squibb Co. - Biography
Oral delivery can be a challenge for active pharmaceutical ingredients (API) with poor aqueous solubility. Solid-state forms such as metastable polymorphs, amorphous solids and multi-component crystals (i.e. salts, cocrystals, solvates, etc.) can improve the solubility. This talk will focus on the design and crystallization of solid forms to enhance solubility through an understanding of the inter-connection between molecular/crystal structures and thermodynamic relationships.
6:45 Dinner Break
7:05 Solid-State Form Screening in Drug Development: Challenges and Opportunities
Sarah L. Price, Ph.D., Professor of Physical Chemistry, Department of Chemistry, University College London - Biography
Susan M. Reutzel-Edens, Ph.D., Senior Research Advisor, Small Molecule Design & Development, Eli Lilly and Company - Biography
8:30 Closing Remarks: Where Are We Now and Where Are We Going?
Harvey Lieberman, Ph.D., Senior Manager, Analytical Research & Development, Sanofi - Biography
I’ll endeavor to sum up the previous speakers’ key points and present some thoughts about the future of crystallization and polymorphism in the context of what has been learned in this short course. Current challenges in polymorph prediction and experimental screening will be discussed.
8:45 Q&A Panel: Participants- All Speakers
9:00 Chairperson’s Closing Remarks and End of Short course
*Separate registration is required
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesNews & AdvertisingKnowledge Foundation IT Trainingprofessional services
executive teamtestimonialschi timelinemailing listcareers